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Abstract
Background This post-hoc sub-analysis investigated
whether age (\65 years vs C65 years) affects glycemic
control or hypoglycemic risk in patients with type 2 dia-
betes mellitus (T2DM) treated with once-daily insulin
detemir.
Methods This was a 26-week, randomized, open-label,
phase IV trial involving 2812 patients at 1083 predomi-
nantly primary care sites throughout the United States, of
which 541 were designated for investigator-led insulin
titration. The main efficacy measure was change in HbA1c
(A1C) from baseline to Week 26. Patients were stratified
by age in the sites designated for the investigator-led
titration of insulin detemir. Safety measures included
adverse events and change in hypoglycemic event rates
from baseline to Week 26.
Results At Week 26, mean A1C and fasting plasma glu-
cose decreased in both groups, but mean differences in
change from baseline were not significant between groups.
Within the group C65 years, significant reductions occur-
red for all daytime hypoglycemia, but there was no sig-
nificant change from baseline in the other categories. In the
group\65 years, reductions from baseline were significant
for all hypoglycemic event categories. Changes in hypo-
glycemia rates from baseline were not significantly
different between the age groups and there was no weight
increase in either age group.
Conclusions This analysis demonstrates that insulin
detemir has similar efficacy and safety profiles for patients
with T2DM C65 years compared with \65 years when
treated via an investigator-led algorithm.
Key Points
This post-hoc analysis presents an exploratory sub-
analysis of efficacy and safety in patients with type 2
diabetes mellitus who were either under or over the
age of 65 years and were treated with the basal
insulin analog, insulin detemir.
Efficacy and safety profiles were found to be similar
with both age groups and the results of this analysis
support the use of a once-daily basal insulin in
lowering HbA1c (A1C) and fasting plasma glucose
while demonstrating a low rate of hypoglycemia and
no weight gain.
This analysis showed that basal insulin may be a
viable option for those aged C65 years and should be
considered earlier in the course of diabetes rather
than reserved for the latter stages of the disease.
1 Introduction
The elderly represent a heterogeneous group with
polypharmacy, comorbidity, and metabolic considerations
associated with advanced age. Therefore, effective diabetes
mellitus management in this group requires a
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comprehensive, multidisciplinary, and individualized
approach. In addition, the lack of large, well controlled
trials makes it difficult to determine which treatment
options would benefit the majority of patients; thus, most
recommendations were extrapolated from data in the non-
elderly [1–5]. Two more recent published guidelines [6, 7]
are evidence-based.
The population of older adults with diabetes is expected
to increase due to the rise in obesity, changing lifestyle, and
the increase in the overall life expectancy of the United
States (US) population [8]. It is estimated that 33 % of
nursing home residents have diabetes and 40 % of the
population is presumed to be prediabetic [9, 10]. This
growing disease burden represents a large public health
concern since diabetes complications are more common
and costly in older individuals who have lived with dia-
betes longer and are more vulnerable to hypoglycemia than
younger patients [1, 11]. Nonetheless, recommendations
for glycemic targets in the elderly are not exclusively
driven by immediate clinical benefits but are also intended
to prevent the untoward effects of pharmacotherapy, par-
ticularly hypoglycemia.
Currently, there are limited published data regarding
basal insulin analog use in older adults, although basal
insulin is the most common and effective recommended
first step in initiating insulin therapy [12, 13]. Some studies
suggest that insulin therapy in the elderly is underutilized
despite available data showing that insulin therapy, par-
ticularly insulin analog therapy, is both safe and effective
in this patient population [14, 15].
This publication presents an exploratory sub-analysis of
efficacy and safety, particularly as it relates to the inci-
dence of hypoglycemia and adverse events (AEs), in
patients aged C65 years and\65 years who were treated
with the basal insulin analog, insulin detemir (Novo Nor-
disk A/S, Bagsvaerd, Denmark), in the investigator-led arm
of the PREDICTIVE
TM
303 trial [16, 17]. This arm was
chosen for analysis because it more closely reflects the
typical practice, where most patients have their basal
insulin levels adjusted by their physicians rather than
adjusting it themselves. The goal of this analysis was to
gain insight into the outcomes for glycemic control in
patients aged C65 years compared with patients younger
than 65 and whose insulin dosing was not self-managed,
somewhat similar to what might occur in long-term insti-
tutional settings.
2 Materials and Methods
This exploratory post hoc sub-analysis of the PRE-
DICTIVE 303 trial [16, 17] examines the efficacy and
safety of insulin detemir in patients with type 2 diabetes
who were stratified by age into two groups, aged
\65 years (n = 1915) and C65 years (n = 897), and
designated for investigator-led titration regimens during
the 26-week trial period. Patients with type 2 diabetes,
aged C18 years, HbA1c (A1C) B12 %, and mean body
mass index (BMI) B45 kg/m2 were eligible for enroll-
ment regardless of their diabetes treatment regimens. Data
included in this post hoc sub-analysis were for patients
who received only one dose of insulin detemir per day.
The trial was approved by institutional review boards, and
all participants enrolled in the trial provided written
informed consent.
2.1 Trial Design and Treatment
Patients were encouraged to maintain contact with their
physician throughout the trial. All subjects participated in a
screening/baseline visit and follow-up visits at Weeks 12
and 26 and received a glucose meter (OneTouch
UltraSmart Milpitas, CA, USA: LifeScan Inc) and test
strips, with appropriate instructions for use. All glucose
measurements performed with capillary blood were auto-
matically calibrated by the meter to plasma-equivalent
glucose values. Insulin detemir was supplied in the
FlexPen (3 mL, 100 U/mL, Bagsvaerd, Denmark: Novo
Nordisk A/S) [16, 17].
Insulin detemir was the only basal insulin used
throughout the trial. The protocol recommended insulin
detemir to be injected once daily in the evening at
approximately the same time each day. Throughout the
trial, patients performed self-measured fasting plasma
glucose (SMFPG) before breakfast on the last 6 days
prior to each scheduled visit. Physicians determined the
initial dose of insulin detemir based on the manufac-
turer’s instructions [17] and adjusted the dose during the
trial according to their standard-of-care practice. During
the first 12 weeks, only the dose of insulin detemir was
to be titrated; in the final 14 weeks, investigators were
encouraged to adjust all medications taken to treat dia-
betes, including prandial insulin doses, where
appropriate.
2.2 Assessments
The main outcomes for efficacy were A1C and the change
in A1C from baseline to the end of the 26-week treatment
period. Change in A1C was analyzed only for patients with
A1C values measured at baseline and at 26 weeks. Addi-
tional outcome variables included FPG, body weight, and
final insulin detemir dose (Table 2). The safety analysis set
(SAS) included all patients who took at least one injection
of insulin detemir after the baseline visit and reported any
safety information.
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2.3 Statistical Analyses
A 2-sided t test with Welch’s correction was used for
comparisons between age groups with respect to changes
from baseline for A1C, FPG, body weight, and insulin
dose. The safety data collected included adverse events and
hypoglycemic events.
In the main PREDICTIVE 303 trial [16], hypo-
glycemic events were defined as (a) symptoms of hypo-
glycemia that resolved with oral carbohydrate intake,
glucagon, or intravenous glucose, and (b) any symptomatic
or asymptomatic blood glucose\56 mg/dL (\3.1 mmol/L).
Nocturnal hypoglycemic events were defined as those
occurring between 2300 and 0600 hours. Severe hypo-
glycemia was defined as an episode of hypoglycemia
during which the patient was unable to self-treat.
Differences in hypoglycemia rates between groups were
analyzed using a Poisson regression model with a log-link
function and the logarithm of the time period in which a
hypoglycemic episode was considered treatment emergent
as offset. All relative risk ratios were adjusted for the
reported total number of years the patient was exposed to
the drug in order to correct for exposure. SAS for Unix
(SAS Institute, Cary, NC, USA), and GraphPad Prism,
version 6 (GraphPad Software, La Jolla, CA, USA), were
used for data analyses.
3 Results
3.1 Demographics
Table 1 lists the baseline demographic characteristics of
patients in the post hoc analysis trial. There were fewer
patients in the group aged C65 years (n = 897) than in the
group aged\65 years (n = 1915). Additionally, patients in
the older group had a longer duration of diabetes
[mean ± standard deviation (SD), 14.3 ± 9.1 years vs
9.8 ± 7.3 years] and lower body weight (92.0 ± 18.5 kg
vs 101.2 ± 21.8 kg) than those aged\65 years. Similar
proportions of patients in both age groups were insulin-
naı¨ve (36.4 and 30.1 % in the \65- and C65-years age
Table 1 Baseline demographic
characteristics—safety
population
Parameter \65 years (n = 1915) C65 years (n = 897)
Age (years)
Mean (SD) 52.3 (8.5) 71.9 (5.4)
Sex, n (%)
Female 921 (48.1) 434 (48.4)
Male 994 (51.9) 462 (51.5)
Missing 0 1 (0.1)
Race, n (%)
White American 1423 (74.3) 732 (81.6)
Black or African American 361 (18.9) 130 (14.5)
Asian 40 (2.1) 9 (1.0)
American Indian or Alaska Native 17 (0.9) 10 (1.1)
Native Hawaiian or other Pacific Islander 3 (0.2) 1 (0.1)
Other 50 (2.6) 12 (1.3)
BMI (kg/m2), n (%) 34.6 (6.3) 32.4 (5.7)
Pre-trial insulin therapy, n (%)
Glargine 684 (35.7) 332 (37.0)
NPH 98 (5.1) 77 (8.6)
Insulin-naı¨vea 697 (36.4) 270 (30.1)
Others 436 (22.8) 218 (24.3)
A1C (%) 8.65 8.22
Fasting plasma glucose (mg/dL) 180.5 160.2
Body weight (kg) 101.2 91.8
Duration of type 2 diabetes
n 1909 897
y, SD 9.8 (7.3) 14.3 (9.1)
BMI body mass index, NPH neutral protamine Hagedorn, SD standard deviation
a Insulin-naı¨ve is defined as patients who took oral anti-diabetes drugs only or did not have therapy as
pretreatment
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groups, respectively) or had prior treatment with insulin
glargine (35.7 and 37.0 % in the\65- and C65-years age
groups, respectively) or neutral protamine Hagedorn
(NPH) (5.1 and 8.6 % in the \65- and C65-years age
groups, respectively).
3.2 Efficacy
Mean baseline values of A1C and FPG were numerically
lower in the group aged C65 years than in the group aged
\65 years (Table 1). Mean differences between groups in
changes from baseline for A1C, FPG, and body weight
were not significantly different (Figs. 1, 2; Table 2).
Starting and ending A1C for patients\65 years were 8.65
and 8.0 %, respectively, compared with 8.2 and 7.7 % for
patients C65 years. Mean estimated A1C difference in
change from baseline between age groups (C65 -\65)
was 0.09 % (p = 0.17). Starting and ending FPG for
patients \65 years were 180.5 mg/dL and 156 mg/dL,
respectively, compared with 160.2 mg/dL and 135 mg/dL
for patients C65 years. Mean estimated FPG difference in
change from baseline between age groups was -3.7 mg/dL
(p = 0.33). Estimated mean differences in body weight
changes from baseline between age groups were not sta-
tistically significant (Table 2). The change in insulin dose
from baseline increased a small amount for both age
groups, with mean estimated differences in change in
insulin dose between age groups of -0.08 units/kg
(p\ 0.0001). Despite the lower A1C achieved in both the
\65- and C65-years age groups, there was no weight gain,
an especially important observation for the C65-years
group who can be unduly burdened by additional weight.
3.3 Safety
Overall, baseline hypoglycemia rates (events/patient/year)
were similar in both groups at treatment initiation (Table 3).
For severe hypoglycemia, the rates were low overall and
remained low throughout the trial (between 5 and 28 events
per 100 patients treated for 1 year). Changes in hypo-
glycemia rates from baseline to end of treatment (Week 26)
were not significantly different between the two age groups.
Rates for all daytime hypoglycemic events were signifi-
cantly decreased within both age groups, and reductions in
severe daytime hypoglycemia were statistically significant
within the group aged\65 years. Nocturnal hypoglycemia
rates changed between one and two events/patient/year
within each age group, and were statistically significant (all
and severe) for the group aged\65 years.
The proportions of patients with reported AEs are shown
in Table 4. The observed percentage of subjects experi-
encing at least one serious AE (SAE) was lower in patients
aged \65 years than in those aged C65 years (5.2 vs
7.7 %, respectively), but the proportion of AEs possibly or
probably related to insulin detemir treatment were similar.
Cardiac disorders were the most common SAE in both age
groups, and occurred in similar proportions of patients in
each age group [18/897 (2.0 %) patients aged C65 years
and 23/1915 (1.2 %) patients aged\65 years]. In patients
aged C65 years, one of the five deaths was due to cardiac
disorders compared with two out of four patients aged
\65 years. Two out of five patients aged C65 years died of
neoplasms (one case of metastatic breast cancer and one
case of abdominal malignancy), with no neoplasms in
patients aged\65 years. No relationship to treatment was
ascribed to the abdominal malignancy, and all other deaths
were characterized by the investigators as unlikely to be
related to insulin detemir.
4 Discussion
In this post hoc analysis of the PREDICTIVE 303 trial
data, mean differences in change from baseline in A1C and



































Fig. 2 Fasting plasma glucose (FPG) (mean ± SE) in patients aged
\65 and C65 years
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aged \65 and C65 years. Baseline hypoglycemia rates
were low for both age groups. Hypoglycemia rates
decreased significantly within each age group, but there
were no significant differences in changes in hypoglycemia
rates from baseline between the groups. This is a clinically
meaningful finding and should encourage the use of basal
insulin in the elderly patient population.
The low hypoglycemia rates for the group aged
C65 years were maintained despite improvements in
A1C. Body weight changes amounted to small, but non-
significant decreases between the two age groups. This
lack of weight gain while achieving improved A1C values
is important, especially in light of the more typical weight
gain observed with insulin use. Final insulin dose was
Table 2 Changes from baseline for A1C, FPG, insulin detemir dose, and body weight in patients aged\65 and C65 years
Parameter \65 yearsa C65 yearsa Mean estimated differences in
changes from baseline between
groupsbn Mean change SD (SE) n Mean change SD (SE)
A1C (%) 1219 -0.56 1.5 (0.04) 584 -0.47 1.3 (0.05) 0.094, p = 0.17
Fasting plasma glucose (mg/dL) 1221 -21.8 83.7 (2.4) 582 -25.5 70.2 (2.9) -3.70, p = 0.33
Insulin detemir dose (U/kg) 1268 0.19 0.3 (0.008) 603 0.11 0.2 (0.008) -0.078, p\ 0.0001
Body weight (kg) 1500 -0.13 5.5c (0.14) 719 -0.49 5.1c (0.19) -0.356, p = 0.13
Data for A1C, FPG, and insulin detemir dose were from the efficacy analysis set; body weight came from the safety set
FPG fasting plasma glucose, SD standard deviation, SE standard error
a Data shown are for observed mean changes within each age group
b Data shown are for differences between age groups for changes from baseline (Day 1) to the end of Week 26 (C65 -\65)
c SD values for body weight changes are large because the gap between the minimum and maximum values was wide
Table 3 Hypoglycemic events
in patients aged\65 and
C65 years
Age (years) Type of hypoglycemia Exposure time All Severe
% R % R
\65 Daytime (n = 1531) Baseline 17.2 6.20 2.2 0.57
Week 26 11.0 3.32a 0.3 0.05a
C65 Daytime (n = 736) Baseline 19.4 6.17 1.9 0.35
Week 26 12.5 4.04a 0.5 0.14 (NS)
\65 Nocturnal (n = 1531) Baseline 7.1 2.25 1.5 0.27
Week 26 4.4 1.25a 0.3 0.07a
C65 Nocturnal (n = 736) Baseline 6.5 1.92 1.0 0.24
Week 26 5.3 2.52 (NS) 0.4 0.28 (NS)
There were no significant differences in changes of hypoglycemia rate when comparisons between age
groups were performed
Significance was based on a generalized linear model with a Poisson distribution and a logarithmic link
function
% represents the proportion of patients reporting at least one hypoglycemic event, where % = n/N 9 100
and n is the number of patients reporting at least one hypoglycemic event
n number of patients who have data on both visits, NS not significant
a Statistically significant difference in rate from baseline, for patients within the indicated age group
Table 4 Adverse events
distribution in patients aged\65
and C65 years
\65 years (n = 1915) C65 years (n = 897)
n % E n % E
Adverse events (AEs) 321 16.8 578 163 33.1 281
Serious adverse events (SAEs) 99 5.2 137 69 7.7 93
Insulin detemir-related AEs (probably/possibly related) 86 4.5 140 32 3.6 58
E number of events
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only slightly higher in the group aged \65 years com-
pared with the group aged C65 years. The difference in
mean change in dose between the two age groups was
statistically significant, but not clinically relevant.
Adverse events related to treatment occurred at similar
rates in both age groups.
This post hoc analysis included some limitations. First,
the trial was not evenly randomized in terms of each group
having equal numbers of patients. Second, there was no
randomization for comorbidities and baseline glucose
parameters. Lastly, investigators were encouraged to adjust
any medication taken to treat diabetes during the last 14
weeks of the trial, including prandial insulin doses. This
could have confounded the results since the number of
patients requiring this intervention may have been different
between age groups. Nevertheless, the results of this sub-
analysis support the use of insulin detemir in the elderly
population with type 2 diabetes. Physicians successfully
titrated insulin detemir to patients aged C65 years with
similar safety and improvements in efficacy seen in
patients aged\65 years.
The results of this current sub-analysis are similar to
other published analyses. A post-hoc analysis [14] con-
ducted on data pooled from three phase III trials comparing
insulin detemir and NPH insulin [18–20] suggested that
insulin detemir can reduce A1C levels with less hypo-
glycemia and less weight gain in both older and younger
persons with type 2 diabetes. A post-hoc analysis of the
original INITIATEplus trial [21] demonstrated that bipha-
sic insulin aspart 70/30 was well tolerated and effective in
patients with type 2 diabetes aged \65 years and
C65 years [22]. The addition of insulin glargine to current
oral anti-diabetic (OAD) therapy for patients C65 years
with poor glycemic control was as effective as increasing
the dose of the OAD and demonstrated lower hypo-
glycemia risk in this patient population [15]. These studies
support the use of insulin analogs in older patients with
type 2 diabetes.
There are few evidence-based studies from which
treatment guidelines for elderly patients can be derived.
The current recommendations are intended to individualize
treatment plans [4, 5, 23, 24]. The risk of hypoglycemia
among patients with type 2 diabetes aged C65 years is
possibly more serious than in a younger population [22].
Therefore, glycemic control in patients aged C65 years
must be carefully balanced with safety, especially hypo-
glycemic risk [22].
The results of this subanalysis support the use of once-
daily basal insulin in lowering A1C and FPG while
demonstrating a low rate of hypoglycemia and no weight
gain. In addition to meeting the needs of patients with type
2 diabetes who are aged \65 years as demonstrated in
earlier trials, this analysis showed that basal insulin may be
a viable option for those aged C65 years and should be
considered earlier in the course of diabetes rather than
being reserved for the latter stages of the disease.
5 Conclusion
Patients with type 2 diabetes treated with insulin detemir
according to physician-led dose titration showed no dif-
ferences in efficacy or hypoglycemia rate changes as a
function of age.
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